LINC00929: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

Target Name: LINC00929

NCBI ID: G503519

LINC00929

Other Name(s): long intergenic non-protein coding RNA 929 | Long intergenic non-protein coding RNA 929, transcript variant 1

LINC00929: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

Introduction

LINC00929 is a long intergenic non-protein coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is located on chromosome 6p and has a length of 2921 nucleotides. LINC00929 is expressed in a variety of tissues and cell types , including brain, heart, and liver. It is highly expressed in the brain and has been shown to be involved in several neural functions, including synaptic plasticity and memory.

Drug Target Potential

LINC00929 is a good candidate for a drug target due to its unique structure and expression pattern. It has a unique open reading frame that is not found in any known protein, and its length allows for targeting potential of different post-transcriptional modifications. LINC00929 has has been shown to play a role in several neural functions, making it an attractive target for small molecules that can modulate its expression and activity.

Biomarker Potential

LINC00929 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and mood disorders. Its expression has been shown to be elevated in several diseases, including Alzheimer's disease, Parkinson's disease, and depression. Additionally, LINC00929 has been shown to be downregulated in several cancer types, making it an attractive target for cancer therapies.

Expression and regulation

LINC00929 is highly expressed in several tissues and cell types, including the brain, heart, and liver. It is expressed at different levels in different cell types, with higher levels in the brain. LINC00929 has been shown to be involved in several neural functions, including synaptic plasticity and memory. It is a key regulator of the neurotransmitter circuitry in the brain and has been shown to play a role in the regulation of neural circuits.

FUNCTIONAL assays have shown that LINC00929 can interact with several protein partners, including casein kinase II, NF-kappa-B, andCREB-1. These interactions may regulate its stability and activity.

Molecular mechanism

The molecular mechanism of LINC00929 is not well understood, but it is thought to play a role in the regulation of gene expression. LINC00929 is a long non-coding RNA, which means it is not coded for by any protein. It is expressed in a variety of tissues and cell types and is highly expressed in the brain.

CONCLUSION

LINC00929 is a long intergenic non-protein coding RNA that has been identified as a potential drug target and biomarker. Its unique structure and expression pattern make it an attractive target for small molecules that can modulate its expression and activity. Additionally, its expression has been shown to play a role in several neural functions, making it a potential target for drugs that can modulate neural function. Further research is needed to understand the molecular mechanism of LINC00929 and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 929

The "LINC00929 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00929 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets